Literature DB >> 18295506

MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively.

Amy Palmer1, Jibran Qayumi, Gabriele Ronnett.   

Abstract

Over 200 mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2) are known to cause Rett syndrome (RTT), a multiphasic neurodevelopmental disorder that results in motor and cognitive impairments; however, little is known about the neurobiology of RTT. Here, we employ the MeCP2(308/y) mouse model of RTT to investigate the course of the neuronal defects imparted by MeCP2 mutation. Using the olfactory system as a neurodevelopmental model, we describe an acute but transient defect in olfactory sensory neuron maturation during synaptogenesis and elaboration of the glomerular neuropil. This defect is overcome through compensatory responses that restore homeostasis. However, a chronic problem in glomerular organization emerges, which eventually leads to increased neuronal apoptosis. This multiphasic course comprising acute developmental and chronic defects in synaptogenesis and maintenance may represent the neurobiological correlates of clinical RTT, and suggests that different therapeutic strategies may be appropriate at different clinical stages of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295506     DOI: 10.1016/j.mcn.2008.01.005

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  15 in total

1.  Normal mitral cell dendritic development in the setting of Mecp2 mutation.

Authors:  A M Palmer; A L Degano; M J Park; S Ramamurthy; G V Ronnett
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

Review 2.  The role of MeCP2 in CNS development and function.

Authors:  Elisa S Na; Lisa M Monteggia
Journal:  Horm Behav       Date:  2010-05-31       Impact factor: 3.587

3.  Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice.

Authors:  Mary E Blue; Walter E Kaufmann; Joseph Bressler; Charlotte Eyring; Cliona O'driscoll; Sakkubai Naidu; Michael V Johnston
Journal:  Anat Rec (Hoboken)       Date:  2011-09-08       Impact factor: 2.064

4.  Loss of MeCP2 in immature neurons leads to impaired network integration.

Authors:  Yi Sun; Yu Gao; Joseph J Tidei; Minjie Shen; Johnson T Hoang; Daniel F Wagner; Xinyu Zhao
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

5.  Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.

Authors:  Garilyn M Jentarra; Shannon L Olfers; Stephen G Rice; Nishit Srivastava; Gregg E Homanics; Mary Blue; Sakkubai Naidu; Vinodh Narayanan
Journal:  BMC Neurosci       Date:  2010-02-17       Impact factor: 3.288

6.  MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function.

Authors:  Alicia L Degano; R Jeroen Pasterkamp; Gabriele V Ronnett
Journal:  Mol Cell Neurosci       Date:  2009-07-21       Impact factor: 4.314

Review 7.  MicroRNAs and epigenetic regulation in the mammalian inner ear: implications for deafness.

Authors:  Lilach M Friedman; Karen B Avraham
Journal:  Mamm Genome       Date:  2009-10-30       Impact factor: 2.957

8.  MeCP2 regulates activity-dependent transcriptional responses in olfactory sensory neurons.

Authors:  Wooje Lee; Jung-Mi Yun; Rima Woods; Keith Dunaway; Dag H Yasui; Janine M Lasalle; Qizhi Gong
Journal:  Hum Mol Genet       Date:  2014-07-09       Impact factor: 6.150

9.  MeCP2 is required for activity-dependent refinement of olfactory circuits.

Authors:  Alicia L Degano; Min Jung Park; Judith Penati; Qun Li; Gabriele V Ronnett
Journal:  Mol Cell Neurosci       Date:  2014-01-25       Impact factor: 4.314

10.  Brain metabolism in Rett syndrome: age, clinical, and genotype correlations.

Authors:  Alena Horská; Luciano Farage; Genila Bibat; Lídia M Nagae; Walter E Kaufmann; Peter B Barker; SakkuBai Naidu
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.